MedTrace Logo

Efficacy Study of ABR-215050 to Treat Prostate Cancer

NCT00560482 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2015-10-26

No results posted yet for this study

Summary

To investigate ABR-215050 as a possible treatment for prostate cancer.

Conditions

Interventions

DRUG

ABR-215050, tasquinimod

Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)

DRUG

Placebo

Identical appearing gelatin capsules containing placebo

Sponsors & Collaborators

  • Active Biotech AB

    lead INDUSTRY

Principal Investigators

  • Goran Forsberg, Assoc. Prof. · Active Biotech AB

  • Roberto Pili, MD · Roswell Park Cancer Institute, Buffalo, New York

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2010-06-30
Completion
2015-08-31

Countries

  • United States
  • Canada
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00560482 on ClinicalTrials.gov